. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug;65(8):1031-8. PubMed.

Recommends

Please login to recommend the paper.

Comments

Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Semagacestat

News

  1. Chicago: Lilly’s Antibody Appears to Do No Harm, But Will It Help?